Post-doctoral Research Fellow Inserm 1037 Cancer Research Center of Toulouse, France
Applications are invited for a two years post-doctoral position on the IMMUSPHINX project coordinated by the T. Levade and N. Andrieu-Abadie's team. This position is funded by the Transcan-2 translational cancer research program (EU framework programme Horizon 2020) and is available starting from April 2017 at the Cancer Research Center of Toulouse (CRCT, Inserm 1037, France).
Project abstract: Immune checkpoint inhibitors (ICI) have shown unprecedented and long-lasting anti-tumor responses, mainly in patients with metastatic melanoma. Nevertheless, novel strategies are urgently needed to increase the number of responders and prevent relapse in melanoma, and to propose new ICI-based treatments in other cancers. In addition, personalized therapies, based on robust prognostic and predictive biomarkers, are necessary to improve resource allocation and toxicity management. Our team has a long-standing knowledge of the sphingolipid (SL) metabolism. We recently discovered that SL metabolism is strongly altered in melanoma, leading to oncometabolites that modify the tumor microenvironment. The IMMUSPHINX project aims at developing new combined therapeutic strategies against melanoma, by targeting both SL metabolism and immune checkpoints, and identifying related prognostic and/or predictive biomarkers. It involves a multidisciplinary research consortium and brings together basic and clinical complementary teams located in France, Spain, Italy and Belgium (http://www.transcanfp7.eu/abstract/immusphinx.html).
The CRCT is located in a campus bringing together public and private stakeholders dedicated to cancer research and care. IMMUSPHINX benefits from a direct access to the core facilities of the CRCT (http://www.poletechno-crct.inserm.fr/en/), including: SPF animal facility, flow cytometry and cell sorting, cellular imaging (confocal microscope and video microscope), vectorology (biosafety L3 laboratory), proteomics, transcriptomics and bioinformatics. It also benefits from close relationships with clinicians involved in cancer treatment at the Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O). Applications are invited for a two years post-doctoral position on the IMMUSPHINX project coordinated by the T. Levade and N. Andrieu-Abadie's team.
Colié S, Van Veldhoven PP, Kedjouar B, Bedia C, Albinet V, Sorli SC, Garcia V, Djavaheri-Mergny M, Bauvy C, Codogno P, Levade T, Andrieu-Abadie N. Disruption of sphingosine 1-phosphate lyase confers resistance to chemotherapy and promotes oncogenesis through Bcl-2/Bcl-xL upregulation.
Cancer Res. (2009) 69:9346-53
Albinet V, Bats ML, Huwiler A, David C, Rochaix P, Chevreau C, Ségui B, Levade T, Andrieu-Abadie N. Sphingosine kinase-1 regulates the paracrine effects of dermal fibroblasts on melanoma cell migration and invasion. Oncogene (2014) 33:3364-73.
Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariamé AF, Touriol C, Rochaix P, Lajoie-Mazenc I, Andrieu-Abadie N, Levade T, Benoist H, Ségui B. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma. Cancer Res (2015) 75:2619-28.
Bertrand F, Rochotte J, Colacios C, Montfort A, Andrieu-Abadie N, Levade T, Benoist H, Ségui B. Targeting TNF alpha as a novel strategy to enhance CD8+ T cell-dependent immune response in melanoma? Oncoimmunology (2015) 5:e1068495.
Mrad M, Imbert C, Garcia V, Rambow F, Therville N, Carpentier S, Ségui B, Levade T, Azar R, Marine JC, Diab-Assaf M, Colacios C, Andrieu-Abadie N.
Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma. Oncotarget. (2016) 7:71873-71886.
This job comes from a partnership with Science Magazine and